Sandeep Menon - Officer Stock Transaction at Biocryst Pharmaceuticals Inc.

On April 6, 2026, Sandeep Menon, Chief R&D Officer at Biocryst Pharmaceuticals Inc. (BCRX), acquired 205,150 shares of Common Stock through an inducement grant under the company's Stock Incentive Plan. This grant vests over four years. Additionally, Menon was granted 441,350 employee stock options, also as an inducement under the Stock Incentive Plan. These options become exercisable in 25% increments over four years, with an exercise price of $9.47 per share. The options are exercisable for Common Stock and expire on April 6, 2036. Both transactions were reported on Form 4, filed on April 7, 2026.